- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | Second Faculty of Medicine
- Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study2017 | First Faculty of Medicine
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | First Faculty of Medicine
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | Second Faculty of Medicine
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study2017 | First Faculty of Medicine
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis2015 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom2022 | First Faculty of Medicine
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis2012 | Second Faculty of Medicine
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | First Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis +12014 | Second Faculty of Medicine
- Dimethyl fumarate in treating relapsing-remittin multiple sclerosis2015 | First Faculty of Medicine, Second Faculty of Medicine